Study details
Enrolling now
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
NCT IDNCT07160335ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18–70
Locations
12 sites in CA, FL, TX +1
What this study is about
This Phase 1 study is testing US-sourced Keytruda® in people with kidney cancer.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
immunotherapy (PD-1 inhibitor immunotherapy (pembrolizumab))
Endpoints
Secondary: Adverse events, DFS, maximum serum drug concentration (Cmax),, maximum serum drug concentration at steady state (Cmax,ss)
Body systems
Oncology